Grace Therapeutics, Inc
GRCE3.000USD
-0.090-2.91%
종가 11/05, 16:00（ET）시세는 15분 지연됩니다
41.49M시가총액
손실P/E TTM
자세한 내용은 Grace Therapeutics, Inc 회사
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.
Grace Therapeutics, Inc 정보
종목 코드 GRCE
회사 이름Grace Therapeutics, Inc
상장일Mar 07, 2013
CEOMr. Prashant Kohli
직원 수- -
유형Ordinary Share
회계 연도 종료Mar 07
주소103 Carnegie Center
도시PRINCETON
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호08540
전화16093221602
웹사이트https://www.gracetx.com/
종목 코드 GRCE
상장일Mar 07, 2013
CEOMr. Prashant Kohli
Grace Therapeutics, Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Vimal Kavuru
Mr. Vimal Kavuru
Independent Chairman of the Board
Independent Chairman of the Board
426.32K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
37.90K
--
Mr. Prashant Kohli
Mr. Prashant Kohli
Chief Executive Officer, Director
Chief Executive Officer, Director
21.36K
--
Mr. Amresh Kumar, Ph.D.
Mr. Amresh Kumar, Ph.D.
Vice President - Program Management
Vice President - Program Management
11.12K
--
Mr. A. Brian Davis
Mr. A. Brian Davis
Independent Director
Independent Director
--
--
Ms. Carrie D'Andrea
Ms. Carrie D'Andrea
Vice President - Clinical Operations
Vice President - Clinical Operations
--
--
Mr. Robert J. Delaversano
Mr. Robert J. Delaversano
Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Managing Director of LifeSci Advisors
--
--
Dr. R. Loch Macdonald, M.D., Ph.D.
Dr. R. Loch Macdonald, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. S. George Kottayil
Dr. S. George Kottayil
Director
Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Vimal Kavuru
Mr. Vimal Kavuru
Independent Chairman of the Board
Independent Chairman of the Board
426.32K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
37.90K
--
Mr. Prashant Kohli
Mr. Prashant Kohli
Chief Executive Officer, Director
Chief Executive Officer, Director
21.36K
--
Mr. Amresh Kumar, Ph.D.
Mr. Amresh Kumar, Ph.D.
Vice President - Program Management
Vice President - Program Management
11.12K
--
Mr. A. Brian Davis
Mr. A. Brian Davis
Independent Director
Independent Director
--
--
Ms. Carrie D'Andrea
Ms. Carrie D'Andrea
Vice President - Clinical Operations
Vice President - Clinical Operations
--
--
수익 분석
FY2021
데이터 없음
지역별USD
이름
수익
비율
Canada
0.00
0.00%
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sun, Aug 17
마지막 업데이트: Sun, Aug 17
주주
주주 유형
주주
주주
비율
Shore Pharma LLC
9.66%
Nantahala Capital Management, LLC
8.52%
SS Pharma LLC
7.80%
Rajitha Grace 2018 Irrevocable Trust
5.65%
AIGH Capital Management, LLC.
4.85%
기타
63.52%
주주
주주
비율
Shore Pharma LLC
9.66%
Nantahala Capital Management, LLC
8.52%
SS Pharma LLC
7.80%
Rajitha Grace 2018 Irrevocable Trust
5.65%
AIGH Capital Management, LLC.
4.85%
기타
63.52%
주주 유형
주주
비율
Corporation
23.11%
Hedge Fund
10.26%
Individual Investor
7.17%
Private Equity
4.85%
Investment Advisor/Hedge Fund
4.24%
Research Firm
3.59%
Investment Advisor
3.46%
Bank and Trust
0.02%
기타
43.30%
기관 주식 보유
마지막 업데이트: Wed, Oct 1
마지막 업데이트: Wed, Oct 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
40
3.65M
26.41%
-351.70K
2025Q2
46
7.78M
66.51%
+1.05M
2025Q1
48
7.92M
57.31%
+1.83M
2024Q4
47
5.99M
59.05%
-359.46K
2024Q3
42
6.02M
59.34%
-98.00K
2024Q2
44
6.05M
59.66%
+810.14K
2024Q1
42
2.77M
33.70%
+1.44M
2023Q4
43
2.08M
26.30%
+647.61K
2023Q3
42
2.06M
26.16%
+1.15M
2023Q2
48
913.80K
16.66%
+138.89K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Shore Pharma LLC
1.34M
9.66%
+147.28K
+12.40%
Jul 18, 2025
Nantahala Capital Management, LLC
1.18M
8.52%
--
--
Jun 30, 2025
SS Pharma LLC
1.08M
7.8%
+147.28K
+15.81%
Jul 18, 2025
Rajitha Grace 2018 Irrevocable Trust
781.59K
5.65%
--
--
Jul 18, 2025
AIGH Capital Management, LLC.
840.08K
6.07%
-143.10K
-14.55%
Jun 30, 2025
BofA Global Research (US)
494.70K
3.58%
--
--
Jun 30, 2025
Kottayil (George)
494.70K
3.58%
--
--
Jul 18, 2025
Kavuru (Vimal)
426.32K
3.08%
--
--
Jul 18, 2025
The Vanguard Group, Inc.
409.10K
2.96%
+153.70K
+60.18%
Jun 30, 2025
Stonepine Capital Management, LLC
292.50K
2.12%
-2.05K
-0.70%
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sun, Nov 2
마지막 업데이트: Sun, Nov 2
이름
비율
Unusual Whales Subversive Republican Trading ETF
0%
Unusual Whales Subversive Republican Trading ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Jul 07, 2023
Merger
6→1
Jul 07, 2023
Merger
6→1
Jul 07, 2023
Merger
6→1
Jul 07, 2023
Merger
6→1
Aug 27, 2021
Merger
8→1
Aug 27, 2021
Merger
8→1
날짜
유형
비율
Jul 07, 2023
Merger
6→1
Jul 07, 2023
Merger
6→1
Jul 07, 2023
Merger
6→1
Jul 07, 2023
Merger
6→1
Aug 27, 2021
Merger
8→1
Aug 27, 2021
Merger
8→1
Aug 27, 2021
Merger
8→1
Aug 27, 2021
Merger
8→1
